Searchable abstracts of presentations at key conferences in endocrinology

ea0014s3.4 | Signaling and regulation of G-protein-coupled hormone receptors | ECE2007

Ago-allosteric effects of agonist drugs on 7TM receptors and their endogenous hormones – example from the ghrelin receptor

Schwartz Thue W.

Conventionally, an allosteric modulator is neutral in respect of efficacy and binds to a receptor site distant from the orthosteric site of the endogenous agonist. However, recently compounds being ago-allosteric modulators have been described i.e. compounds acting both as agonists on their own and as enhancers for the endogenous agonists in both increasing agonist potency and often providing additive efficacy - superagonism. The additive efficacy can also be observed with ago...

ea0014s13.4 | Glucocorticosteroids | ECE2007

Glucocorticoid sensitivity: consequences for the clinic?

Koper Jan W

Glucocorticoids (GCs) exert a wide variety of functions throughout the human body, including mediation of the stress response, regulation of lipid and glucose metabolism, immunosuppressive and anti-inflammatory actions, vascular effects, increase of bone resorption, as well as effects on the development and function of numerous organs. The immuno-suppressive effects of GCs are routinely used in the treatment of chronic inflammatory or immune diseases (e.g. inflammatory bowel d...

ea0011p195 | Clinical practise and governance | ECE2006

Long-term outcome in men with microprolactinoma

Rea R , Jeffcoate W

Introduction: It is accepted that hyperprolactinaemia associated with microprolactinoma may prove self-limiting in 25–30% women, and there is some suggestion from series of mixed gender that the same may be true in men.Methods: We have therefore reviewed the outcome in all men with microprolactinomas managed at the Department of Diabetes and Endocrinology, City Hospital, Nottingham, between 1994 and 2002. All had sustained and previously untreated h...

ea0011p364 | Diabetes, metabolism and cardiovascular | ECE2006

Anti-oxidative effect of 17beta-estradiol in human endothelial cells: the role of Bcl-2

Zhong W , Atkin SL

Aim: To determine if the endogenous estrogen 17beta-estradiol protected against oxidative stress-induced endothelial cell damage and the mechanism of this potential effect.Methods: Human umbilical vein endothelial cells were isolated and cultured in phenol red free media with 2% charcoal-stripped serum. The following were undertaken (1) Cells were exposed to 0.1 to 1 nM 17beta-estradiol immediately prior to 100 μM hydrogen peroxide added for 24 hour...

ea0009p38 | Growth and development | BES2005

Modulation of somatostatin receptors expression by genistein in human umbilical vein endothelial cells

Zhong W , Atkin S

Background Somatostatin has various biological effects such as modulation of exocrine and endocrine secretions, proliferation and apoptosis. These effects have been shown to be mediated via G-protein linked receptors known as somatostatin receptors 1-5 (SST 1-5). It has been shown that SST 2 in particular can be modulated by estrogen. The phytoestrogen genistein acts through the estrogen receptor beta and has been shown to have opposing effects on cell proliferation at differe...

ea0009p198 | Clinical | BES2005

Bromocriptine-sensitive acidophil-stem-cell adenoma co-secreting growth hormone and prolactin - A case report

D'Costa R , Kalk W

Case HistoryWe report a 28-year-old man who presented initially to our ENT department with 3-year history of intermittent epistaxis subsequently found to have an extensive acidophil-stem-cell adenoma, rare pituitary tumours usually unresponsive to dopamine agonists requiring radiotherapy and somatostatin analogues in resistant cases.He was clinically acromegalic, demonstrating an elevated Growth Hormone (GH) 17.9 milliunits per lit...

ea0007p264 | Clinical case reports | BES2004

Hyponatremia and recurrent abdominal pain

Prakash P , Stephens W

A 49 year old lady was referred to the endocrine clinic for investigation of intermittent hyponatremia. She had two admissions in the year with lower abdominal, back pain and dark urine and treated for urinary infections.Serum sodium was 112,114 millimoles per litre, which responded to fluid restriction.She had a past history of syncopal episodes, hypertension treated with atenolol, amlodipine. She was a nonsmoker, alcohol intake was 14 units per week.</...

ea0005p247 | Steroids | BES2003

Can random urine samples substitute for 24 hour collections for steroid profiling?

Jerjes W , Taylor N

Urinary steroid profiling by capillary gas chromatography is useful for identification of disordered steroid metabolism and, when 24h collections are made, for determination of steroid production rates. We have noted a substantial clinical demand for analysis of random collections, most commonly from children with precocious puberty and a general belief that relating steroid levels to creatinine would offset the disadvantage of a short collection. Given the known circadian var...

ea0003p54 | Clinical Case Reports | BES2002

Apparent mineralocorticoid excess caused by Barnips cough tablets

Lewandowski K , Burr W

Presentation: A 66 year old woman, was admitted as an emergency with one week history of profound weakness ('had to crawl to the fridge to get milk for tea'), lethargy, productive cough and hypokalaemia (GP results: Na 141, K 1.5, bicarbonate 47 (23-28), Creatinine 54 (μmol/l). Her medication: Amlodipine 5 mg od, Bendrofluazide 2.5 mg od, Aspirin 75 mg.PMH: hypertension, moderate COPD and peripheral vascular disease. She smoked 20 cigarettes a day an...

ea0029p353 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Long-term efficacy and safety of pasireotide in Cushing’s disease: a 36-month case report

Ning G. , Wang W. , Maldonado M. , Trovato A. , Zhou W.

Background: A recent, large phase III study (n=162) showed that treatment with pasireotide rapidly decreased urinary free cortisol (UFC) levels and improved signs and symptoms in patients with Cushing’s disease. Here, we report the experience of a patient enrolled in this trial who received pasireotide for 36 months.Results: A 31-year-old male presented in June 2008 with persistent Cushing’s disease despite two previous pituitary surgica...